HC Wainwright & Co. Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $1201
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $1245 to $1201.
HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $1245 to $1201.